SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending downwards, driven by concerns over increasing competition from Amazon and its recent deal with Netflix. Community discussions revolve around whether the stock is oversold, potential bottom levels, and CEO Jeff Green's strategy amidst these challenges, with some speculating about a possible acquisition or management change to revive investor confidence.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus Inc. ($NUKK) is trending due to the recent withdrawal of a planned share offering, sparking speculation about potential mergers/acquisitions and short squeezes. The community is discussing potential defense contracts related to the Tiltan deal and AI applications, with some focused on technical breakouts and price targets. The stock's low float and high short interest are fueling volatility and potential for significant price swings.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu ($SAILANA.X) is trending as its "Wolfpack" community rallies around the token, anticipating a significant breakout and drawing comparisons to past meme coin successes like Shiba Inu. The community emphasizes its strong base, dedicated developers, and a shared conviction that Sailana Inu is poised for substantial growth. Some users cite recent whale activity as a bullish signal.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following an RBC Capital upgrade to Outperform, with a significantly raised price target driving bullish sentiment. Community discussions revolve around the potential for a short squeeze and the stock's long-term growth prospects in the African e-commerce market. Investors are also watching for a potential breakout above the $10 resistance level.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is trending due to heightened interest in its fuel cell technology for powering AI data centers, particularly after Oracle selected Bloom for its data centers. Community members are discussing the potential for more deals with major data center developers, with some anticipating a significant short squeeze. Analysts have increased the price target, citing the company's positioning to meet rising power demands and cost-reduction initiatives.

Slopana

Slopana is gaining traction as a Solana-based meme coin, fueled by community enthusiasm and increasing visibility on Phantom Wallet. Discussions center on its potential as the next big meme coin, with some community members drawing attention to a doxxed leader. The coin's association with the term 'digital slop' within the Solana ecosystem is also a key talking point.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

Shares of uniQure are trending amid community discussion around recent analyst ratings and the potential for accelerated approval of their Huntington's disease treatment, AMT-130. While some express optimism about uniQure's pipeline and regulatory progress, others voice concerns regarding management and historical stock performance, contributing to a volatile trading environment. Community members are actively debating the company's future prospects and potential catalysts.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

$QKITTY.X is trending with bullish sentiment, partly fueled by a recent airdrop in collaboration with $BROKE.X. The community is also excited about the trading bot feature offering daily interest, contributing to positive discussions around potential gains and future developments within the Solana ecosystem.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending as investors discuss its recent pullback and potential buying opportunities, highlighted by a $500M share buyback announcement. The community is debating whether the stock is oversold and if expansion into Asia will be a positive catalyst. Discussions also include concerns about current pricing and the overall consumer environment.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders discuss potential market volatility amidst geopolitical tensions and economic uncertainty, with some anticipating a significant spike. Community members are debating entry points, potential price targets, and strategies, while also expressing frustration with the ETF's performance relative to the VIX. Concerns around rate cuts and their potential impact on the market are also fueling the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cadrenal Therapeutics, Inc. (CVKD) on Monday announced the acquisition of new assets from eXIthera Pharmaceuticals.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/15/3149938/0/en/Cadrenal-Therapeutics-Enhances-Anticoagulation-Pipeline-Through-Acquisition-of-eXIthera-s-Portfolio-of-Factor-XIa-Inhibitors.html">said</a> that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings. As per the deal, eXIthera will receive milestone payments from Cadrenal totaling up to $15 million, subject to the realization of certain future clinical and regulatory milestones. eXIthera will also be entitled to royalties on global sales of the acquired assets upon future commercialization.CVKD shares jumped 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The deal includes eXIthera’s portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, a new class of anticoagulants. This includes eXIthera’s lead asset, Frunexian, being studied for acute anticoagulation, EP-7327, an oral small molecule candidate for chronic indications, and an extensive portfolio of additional small molecules.“With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Cadrenal CEO Quang X. Pham.“With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk,” he added.Sichuan Haisco Pharmaceuticals retains rights to Frunexian in China under a pre-existing license agreement, the company said. Cadrenal will, however, be entitled to receive royalties of Frunexian sales in China.CVKD stock is down 8% this year but up approximately 20% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-rate-cut-this-week-too-late-powell-bigger-than-he-had-in-mind/chwwONNRdUh">Trump Says ‘Too Late’ Powell Must Cut Rates Now, And ‘Bigger Than He Had In Mind’ Ahead Of Fed Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.

Equity

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new...

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K...

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat at the Lytham Partners 2025...

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as a superior and safer chronic...

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January...

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook PR...

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE PR Newswire PONTE VEDRA, Fla., Nov. 7, 2024 PONTE VEDRA, Fla., Nov. 7, 2024...

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds PR Newswire PONTE VEDRA...

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility PR Newswire PONTE VEDRA, Fla., Oct. 24, 2024 PONTE VEDRA...

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

CVKD
Cadrenal Therapeutics, Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CVKD News

CVKD Cadrenal Therapeutics, Inc.